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based on lactose octaacetate:octapropionate 1 :1 containing 3 m M PLA-DTPA(Gd), 40% triglyceride, 5% propylene carbonate and
10% XSAIB (sucrose based CT-contrast agent). The injectable marker had high C T contrast (> 1000 HU) and displayed clearly visible,
stable T i contrast enhancement (T ~900 n s) in the rim over at least 3 weeks with clinically observable resolution. Key words: Fiducial
marker, MRI, CT, Image Guided Radiotherapy
Development of injectable fiducial markers for image guided
radiotherapy with dual MRI and CT visibility
Introduction
Radiation therapy or radiotherapy (RT) is an important therapy form used in
combination with surgery and chemotherapy for the treatment of cancer [ 1 ] .
Radiotherapy relies on the use of ionizing radiation, and is therefore very
dependent on precision and accuracy. Therefore, increasing emphasis is being
laid on optimizing radiotherapy volume while facilitating tumor targeted delivery
of high radiotherapy doses, resulting in a more efficient treatment with reduced
risk of radiation damage to adjacent normal tissues [2]. Image Guided
Radiotherapy (IGRT). IGRT facilitates more accurate position verification
during the course of fractionated radiotherapy in order to correct for change in
tumor position related to internal organ movement caused by respiration,
peristalsis and rectal/ bladder filling [3]. Thereby IGRT helps reduce toxicity of
radiation treatment while leading to a higher fraction of relapse-free survival [4].
The most frequently used imaging-technique for IGRT is Computed
Tomography (CT) due to its ability to visualize tumors in both a time- and cost-
effective manner. However, CT-based target delineation of soft tissue tumors
tends to only improve the precision and not the accuracy of tumor delineation
for radiotherapy treatment. An important reason for this is the relatively low soft
tissue resolution of this imaging technique [5, 6]. An example of this was seen
by Gao et al [7], by comparing prostate delineations on CT with anatomical
photos, an overestimated target volume of -30% was observed on CT,
comparable to the differences in target delineation between CT and MRI. For
example, on average, -40% larger prostate volumes are defined on CT
compared to MRI, a technique with submillimeter soft tissue resolution [7, 8, 9].
CT-delineations of the prostate also tends to underestimate the dimensions in
the posterior direction, here MRI has a clearly more accurate visualization of
prostate anatomy [7, 10, 11] . These observations clearly indicate that it is
advantageous to apply both CT and MRI in planning of soft tissue tumor
radiotherapy in order to obtain images with sufficient resolution and accurate
dimensions. An inter-correlation point with a fixed position and volume (a
marker) can be applied to guide treatment planning on both CT and MRI
imaging. Such a marker would allow for an easy correlation between the two
imaging modalities and a fixpoint to track moving soft tissue tumors on CT in
real time during treatment [ 1 0].
Fiducial markers are used in IGRT in order to track soft tissue tumors in moving
tissues where the actual position cannot clearly be correlated to bony anatomy,
which is the case for most tumors in abdominal organs and in the lungs [ 1 2,
13]. Injectable, fiducial markers based on SAIB (Sucrose Acetate Isobutyrate),
ethanol and gold-nanoparticles or a iodine-rich sucrose esters (XSAIB) have
been developed in order to improve a technology formerly dominated by solid,
difficult to administer markers such as gold seeds [ 13,14]). The novel SAIB-
based fiducial markers are easily administered, non-toxic, biodegradable
markers with high CT contrast and high stability over the entire course of
radiotherapy [3, 15]. While SAIB-based markers are readily visible in the CT
modality due to the high content of heavy atoms (Au or I), the markers result in
a hypointense signal in Ti-weighted MRI, often difficult to visualize in tumor
tissue [ 1 6]. In order to facilitate better visualization in the MRI modality, a Gd
chelating moiety can be incorporated in the fiducial marker formulations,
resulting in a positive (bright) Ti contrast, easily visualized in the tumor area
[ 1 7]. Gd-complexes provide high Ti contrast enhancement and are highly
stable. They work by shortening of the Ti relaxation of surrounding water
molecules.
Gd chelating injectable gels and gel-like formulations are known from literature
as a means of achieving high local Ti contrast due to stable, slow tumbling,
poly-functionalized complexes often constructed from polymeric materials [ 1 8].
The systems described in literature mainly consist of hydrophilic
polysaccharides such as chitosan and hyaluronan functionalized with Gd
chelators [ 19, 20] displaying high Ti contrast and retention in tumors lasting
several days, however these hydrophilic systems are often not injectable in
sufficiently high concentrations, therefore nanoparticle formulations are
constructed, and clearance of such particles is relatively fast (within days) from
the tumor area, requiring repeated administration. Formulations injectable
through thin needles in long endo- or bronchoscopes (EUS/EBUS) and capable
of retaining the same size and shape over the typical 6-week period of a
fractionated radiotherapy regime, represent the most optimal design.
Therefore, the design described in this article is based on injectable, non-
viscous formulations of different lactose esters (octaacetate:octapropionate 1: 1
or octaisobutyrate) co-formulated with low percentage of solvent and/or short
chain triglycerides. The hydrophobicity of the formulations can be tuned to fit
the loaded contrast agents as well as therapeutic molecules such as
radiosensitizers or other therapeutic molecules loaded in the material to
potentiate the effect of radiotherapy. The formulations contain 10 wt% XSAIB
(6,6'-di-triidobenzene-isobuturic-sucrose,) as CT contrast agent and
amphiphilic or hydrophilic Gd-chelating molecules (lipids or polymers) as MRI
contrast agent. While the hydrophobic CT contrast agent is relatively uniformly
distributed throughout the whole formulation, the amphiphilic or hydrophilic Gd-
chelating constructs are capable of diffusing to the rim of the material upon
injection, providing contrast enhancement at the rim (Figure 1) . The presented
design provides a clear distinction between CT contrast and MRI contrast in
the marker. The work presented in this article provides promising initial results,
indicating a clinically applicable concept under development.
Summary of the invention
The present invention is directed to a composition for at least MR imaging,
comprising non-water soluble carbohydrates, wherein at least 50% of the
non-water soluble carbohydrates are carbohydrates selected from derivatives
of lactose, maltose, trehalose, raffinose, glucosamine, galactosamine,
lactosamine, sucrose or derivatives of sucrose, or mixed saccharides, or
derivatives of disaccharides with at least two pyranose saccharide units,
trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the
composition is a liquid before administration into the human or animal body
and increases in viscosity by more than 1,000 centipoise (cP) after
administration, for use as a medicament, wherein the composition contains at
least one imaging contrast agent, and wherein the composition provides a
phase separation which provides a clear contrast distinction in MR imaging.
To relate further to prior art, WO201 4/1 87962 discloses an X-ray contrast
composition for local administration, wherein the X-ray contrast composition
exhibits contrast properties and wherein at least 60% of an administrated
amount of said X-ray contrast composition remains more than 24 hours within
10 cm from an injection point when the X-ray contrast composition is
administrated to a human or animal body.
Moreover, in WO201 6/079330 there is disclosed a composition comprising
non-water soluble carbohydrates, wherein at least 50% of the non-water
soluble carbohydrates are carbohydrates selected from derivatives of lactose,
maltose, trehalose, raffinose, glucosamine, galactosamine, lactosamine, or
derivatives of disaccharides with at least two pyranose saccharide units,
trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the
composition is a liquid before administration into the human or animal body
and increases in viscosity by more than 1,000 centipoise (cP) after
administration, for use as a medicament.
None of the documents above relate to a composition providing a phase
separation such as the composition according to the present invention. The
phase separation provided according to the present invention enables the
provision of a clear contrast distinction in MR imaging, and especially when
MR imaging and CT is combined. This is not hinted or disclosed in
WO201 4/1 87962 or WO201 6/079330.
Experimental procedures
Organic synthesis
General experimental conditions: All reactions were carried out under inert
atmosphere (N2). Water sensitive liquids and solutions were transferred via
syringe. Water used for washing of the syntheses was in all cases pure MiliQ
water. Organic solutions were concentrated by rotary evaporation at 30-60°C
under 200-0 milibar. Thin layer chromatography (TLC) was carried out using
aluminium sheets pre-coated with silica 60F (Merck 5554). The TLC plates
were inspected under UV light or developed using a cerium ammonium
sulphate solution ( 1 % cerium(IV)sulphate and 2.5% hexa-ammonium
molybdate in a 10% sulfuric acid solution).
Reagents: DOTA-NHS was purchased from Macrocyclics. All other chemicals
were purchased from Sigma Aldrich and were used as received. Dry pyridine
was obtained by drying over sieves (4A) for 2-3 days prior to use.
Instrumentation: Nuclear Magnetic Resonance (NMR) was conducted on a
Bruker Ascend Tm 400 MHz - operating at 401 .3 MHz for H and 100.62 MHz for
3C - with a 5 mm H - Broadband Dual Channel z-gradient Prodigy cryoprobe
at 298 K, using the residual solvent as internal standard. Recorded chemical
shifts were reported in parts per million (δ = scale) downfield from
tetramethylsilane, and all coupling constants (J) are expressed in Hz. The FID
files were processed in Mnova Suite version 8.1 .4. In H-NMR spectra of ,β
anomeric mixtures, the integral of H-1 of the most abundant anomer was
always set to 1.0, and the percentage of each anomeric species was calculated
from the integral ratio of H-1 a and H-1 β. MALDI-TOF MS was conducted on
a Bruker Autoflex Speed Tm instrument. The matrix used for MALDI-TOF was a
mixture of 2,5 dihydroxy benzoic acid (DHB), trifluoroacetic acid and Na+ in
ethanol. Preparatory HPLC was conducted on a Waters 600 pump and
controller with a Waters 2489 UV/Vis detector.
General experimental procedure for synthesis of lactose
esters
β-lactose (typically 10-1 00 g) was suspended in dry pyridine under inert
atmosphere (N2). Hereafter, acetic, propionic or isobutyric anhydride (-2.2 eq
pr OH) was carefully added, followed by a catalytic amount of DMAP (-0.1 eq).
The reactions were heated to ~48°C overnight and then continued for -24 H at
r.t. The reactions were then concentrated in vacuuo and co-evaporated with
toluene. The concentrates were dissolved in CHC and washed with NaHCO3
(aq) (3x), water (2x), and brine ( 1 x). The organic phases were dried with
MgSO (s), filtered, concentrated under reduced pressure and dried in vacuuo.
,β lactose octaacetate. Yield: 93.7 % yield (mixture of anomers: -30% a and
-70 % β) . Η-ΝΜΡ : (400 MHz, Chloroform-d) δ 6.24 (d, J = 3.7 Hz, 0.4H, H-1
a), 5.66 (d, J = 8.3 Hz, 1H, H-1 β) , 5.44 (dd, 0.28, 9.53 Hz, 0.4 H), 5.37 - 5.31
(m, 2H), 5.23 (t, J = 9.1 Hz, 1H), 5.1 5 - 5,00 (m, 3H), 4.99 - 4.91 (m, 2H), 4.50
- 4.41 (m, 3H), 4.1 7 - 4.05 (m, 4H), 3.99 (ddd, J = 10.2, 4.3, 2.1 Hz, 0.4H, H5
a), 3.91 - 3.78 (m, 3H), 3.75 (ddd, J = 9.9, 4.8, 2.0 Hz, 1H, H5 β) , 2.1 9-1 .93
(singlets, -32 H, CH3 acetyls). MALDI TOF-MS: Calc [M+ Na]+: 701 .59. Found:
701 .51 . ,β lactose octapropionate. Yield: 84% (mixture of anomers: -30% a
and -70 % β) . H-NMR (400 MHz, Chloroform-d) δ 6.26 (d, J = 3.7 Hz, 0.4H,
H 1-a), 5.68 (d, J = 8.3 Hz, 1H, H-1 β) , 5.47 (dd,1 0.3, 9.2 Hz,0.4 H), 5.38 - 5.33
(m, 2H), 5.26 (t, J = 9.2 Hz, 1H), 5.1 5 -5.00 (m, 3H), 5.02 - 4.91 (m, 2H), 4.49
- 4.41 (m, 3H), 4.1 5 - 4.03 (m, 4H), 3.98 (ddd, J = 10.1 , 3.9, 1.8 Hz, 0.4 H, H5
a), 3.91 - 3.77 (m, 3H), 3.73 (ddd, J = 9.9, 4.6, 2.0 Hz, 1H, H5 β) , 2.47 - 2.1 5
(m, ~23H), 1. 1 9 - 0.99 (m, ~34H). MALDI TOF-MS: Calc [M+ Na]+: 8 13.80.
Found: 8 13.42. ,β lactose octaisobutyrate. Yield: 89,5% (mixture of anomers:
-30% a and -70 % β) . H NMR (400 MHz, Chloroform-d) δ 6.26 (d, J = 3.8 Hz,
0.4H, H-1 a), 5.68 (d, J = 8.3 Hz, 1H, Η- 1 β) , 5.48 (dd, J = 10.3, 9.3 Hz, 0.4 H),
5.40 - 5.34 (m, 2H), 5.27 (t, J = 9.5 Hz, 1H), 5.1 8 - 5.00 (m, 3H), 5.03 - 4.91
(m, 2H), 4.50 - 4.41 (m, 3H), 4.24 - 4.02 (m, ~4H), 3.95 (ddd, J = 10.1 , 3.8, 1.7
Hz, 0.4H, H5 a), 3.91 - 3.80 (m, 3H), 3.70 (ddd, J = 9.9, 4.5, 2.0 Hz, H, H5 β) ,
2.70 - 2.32 (m, ~ 1 1H), 1.26 - 1.01 (m, -68 H). MALDI TOF-MS: Calc [M+ Na]+:
926.02. Found: 925.70.
PLA-RhB. PLA-NH2 (Mn -2500) (260 mg, 0.1 mmol) was suspended in dry
DCM (~5 ml_). Then, a pre-mixed mixture of Rhodamine-B ( 105, 0.2 mmol),
EDC-HCI (80 mg, 0.4 mmol) and DMAP ( 106 mg, 0.9 mmol) dissolved in 5 ml_
dry DCM was added, and the reaction was continued at r.t. for 2 days, where
after Kaiser test (negative) indicated completion. The solvents were removed
in vacuuo, and the crude mixture was dissolved in DMSO and purified by
dialysis (Mw cutoff: 1000 da) against MQ water for 14 days. Yield: 299 mg
(97%). H NMR (400 MHz, DMSO- ) δ 8.31 (d (br), J = 7.7 Hz, 1H), 7.95 (br.
t , J = 7.4 Hz, 1H), 7.87 (br. t , J = 7.6 Hz, 1H), 7.57 - 7.44 (m, 2H), 7.05 - 7.00
(m, 1H), 6.39 - 6.24 (m, ~5H), 5.20 (q, J = 7.1 Hz, ~33H), 3.65 (dd (br), J=1 3.8,
6.9 Hz, 4H), 3.31 (br. q, J = 7.1 Hz, 8H), 3.1 2 - 2.94 (m, 2H), 1.47 (d, J = 7.1
Hz, ~99H), 1.08 (t, J = 6.9 Hz, 12H).
PLA-DTPA. PLA-NH2 (Mn -2500) (260 mg, 0.1 mmol) was suspended in dry
pyridine (-1 0 ml_) followed by addition of DTPA-dianhydride (57.5 mg, 0.1 6
mmol) followed by a catalytic amount of DMAP ( 1 .3 mg, 0.01 mmol). The
reaction was continued for - 1.5 day, where after Kaiser test (negative)
indicated that the reaction was completed. - 5 ml_ MQ water was added and
stirred for - 2 h to hydrolyze the anhydride. The solvents were removed in
vacuuo, and the crude mixture was dissolved in DMSO and purified by dialysis
(Mw cutoff: 1000 da) against MQ water for -8-1 0 days. Yield: 285 mg (96%).
H NMR (400 MHz, DMSO- ) δ PLA-DTPA, DMSO-D6: 8.09 (s, NH, ~ 1 H),
5.20 (q, J = 7.0 Hz, -33H), 4.21 (dd, J = 6.0 Hz, 12.0 Hz, 2H), 4.1 7 - 4.01 (m,
4H), 3.45 (s, 2H), 3.38 (s, 2H), 3.26 (s, 2H), 3.1 4 (dd, J = 12Hz, 6.0 Hz, 2H),
2.99 (s, 2H), 2.86 (s, 2H), 2.70 - 2.64 (m, 2H), 2.35 - 2.29 (m, 2H), 1.74 (p, J
= 7.0 Hz, 2H), 1.47 (d, J = 7.1 Hz, -99H).
PLA-DOTA. PLA-NH2 (Mn -2500) (80 mg, 0.032mmol) was suspended in dry
dichloromethane (~3 mL), followed by addition of DOTA-NHS (35 mg, 0.0704
mmol) and triethyl amine (40 µ Ι_). The reaction was continued for -2.5 days at
r.t., where after Kaiser test (negative) indicated completion. The solvent was
removed in vacuuo, and the crude mixture was dissolved in DMSO and purified
by dialysis (Mw cutoff: 1000 da) against MQ water for -8-1 0 days. Yield: 89.6
mg (-97%). H NMR (400 MHz, DMSO- ) δ 8.23 (s, NH, - 1H), 5.21 (q, J = 7.0
Ηζ,- 33H), 4.21 (dd, J=1 3.6, 6.8 Hz, 2H), 4.09 (2 x dd, J = 13.6, 6.8, 2H), 3.42
(d of s, 6H), 3.22 - 3.03 (m, -6H), 3.03 - 2.87 (m, - 1OH), 2.65 (d of s, 2H), 1.79
(p, J = 6.9 Hz, 2H). 1.47 (d, J = 7.0 Hz, -99H).
DOPE-DOTA. Diacylphosphatidylethanolamine (DOPE) ( 12 mg, 0.01 6 mmol)
was suspended in dry dichloromethane (-3 mL), followed by addition of DOTA-
NHS (-1 8 mg, 0.036 mmol) and triethyl amine (50 µ ) . The reaction was
continued for -2.5 days at r.t., where after kaisertest (negative) and MALDI-
TOF of reaction mixture indicated completion. The solvent was removed in
vacuuo, and the crude mixture was dissolved in MeOH:H2O 40:60 and purified
by preparative HPLC (Xterra C8 column, MeCN/H 2O/TFA system. Gradient:
50->1 00% MeCN in 10 minutes). Yield: 13.5 mg, 74%. H NMR (400 MHz,
Chloroform-d) δ 7.93 (s, 1H), 5.39 - 5.28 (m, 5H), 5.21 (dddd (br), J = 5.6, 3.0
Hz, 1H), 4.21 (dd, J = 12.0, 3.1 Hz, 1H), 4.32 (dd, J = 12.1 , 6.8 Hz, 2H), 4.1 1 -
4.01 (m, 2H), 3.89 (t, J = 6.4 Hz, 2H), 3.49 (dd, J = 14.6, 7.3 Hz, 8H) 3.09 (dd,
J = 14.6, 7.3 Hz, 15 H), 2.63 (s, 7.5 Hz, 6H), 2.25 (dt, J = 10.0, 7.5 Hz, 4H),1 .97
(q, J = 6.4 Hz, 8H), 1.40 - 1. 1 3 (m, ~42H), 0.84 (t, 6H). MALDI-TOF MS: Calc
[M+ H]+: Calc 113 1 .45, Found: 113 1 .5.
Formulation
The carbohydrate materials as well as the Gd-chelating PLA, PLA-RhB and
DOPE-DOTA were used after the synthesis described under the organic
synthesis section. DOPE-RhB, DOPE-CF and BSA-DTPA(Gd) were purchased
from Avanti Polar Lipids, INC. Absolute EtOH (99%) was purchased from CCS
Healthcare. Glycerol trihexanoate (GTH) was purchased from CHEMOS
GmbH. PBS was purchased from Fischer Scientific ((Dulbecco's Phosphate
buffer saline. Without calcium, magnesium and phenol red). XSAIB (CT-
contrast agent) was kindly provided by Nanovi Radiotherapy. All other additives
(triglycerides and solvents) were purchased from Sigma Aldrich. All
compounds were used as received from the manufacturer.
Preparation of formulations containing DOPE-RhB or DOPE-
CF
DOPE-RhB was dissolved in EtOH or triglycerides and added to the
formulations in amounts resulting in the desired final concentrations ( ~ 1.3* 10
3ug/uL) in formulations consisting of lactose acetate:propionate 1: 1 /lactose
isobutyrate co-formulated with either 25wt% EtOH or 40wt% triglyceride
(GTO/GTH), with or without 10wt% EtOH or 5wt% PC (-240 uL formulations in
total). The DOPE-RhB solutions were made from a motherstock of 1 mg/mL
DOPE-RhB in EtOH with serial dilution into EtOH/triglyceride (GTO/GTH). The
injected formulations were imaged in PBS in 8-well microscope slides under
the confocal microscope.
DOPE-CF was dissolved in EtOH or triglycerides in concentrations of 1 mg/mL.
10 uL of this stock was added to -230 uL carbohydrate formulation to give
concentrations of ~ 0,042 ug/uL in formulations consisting of lactose
acetatepropionate 1:1/lactose isobutyrate co-formulated with either 25wt%
EtOH or 40wt% triglyceride (GTO/GTH), with or without 10wt% EtOH or 5wt%
PC. The formulations were imaged in PBS in 8-well microscope slides under
the confocal microscope.
Preparation of PLA-RhB formulations
PLA-RhB (Mn~3000) was dissolved in EtOH in concentrations of 5 mg/mL and
diluted 100 times into triglyceride (GTH or GTO). -30 uL of this solutions were
added to -21 0 uL carbohydrate formulation to give concentrations of - 0.0063
ug/uL in formulations consisting of lactose acetate:propionate 1: 1 /lactose
isobutyrate co-formulated with 40wt% triglyceride (GTO/GTH) with or without
10wt% EtOH or 5wt% PC. The formulations were imaged in PBS in 8-well
microscope slides under the confocal microscope.
Preparation of formulations containing Gd-chelating
molecules
Carbohydrate esters (45 wt%) and and XSAIB ( 10 wt%) were weighed off into
a glass vial, followed by addition of tBuOH:water solutions of the Gd-chelator
in the wanted concentrations after finished freeze-drying and formulation (3
mM,1 .5 mM, 0.75 mM and 0.3 mM). Acqueous solutions of GdCb were also
added to give the same concentrations of both chelator and Gd in the finished
materials. The solutions were freeze-dried overnight and subsequently mixed
GTH (40 wt%), and PC (5wt%) applying ultrasonication (typically at 40-60°C)
and vortexing until homogeneiety. The formulations were either used the same
day or later after a bit of ultrasonication/vortexing to assure homogeneiety.
Confocal Microscopy
Laser Scanning Confocal Microscopy was performed using a Leica TCS SP5
Scanning Laser Confocal Microscope operated using a 6 1x wet objective and
a 561 nm excitation DPPS Laser. Samples (-5-1 0 uL) were prepared in 8 well
microscope slides containing PBS buffer and imaged on the same day to study
the distribution of fluorescence signal within the material. In case of Rhodamine
B, emission was detected between 575 and 674 nm, while in case of carboxy
fluorescein emission was detected between 480 and 580 nm. Multiple images
were acquired for each sample and z-stack images were acquired with a 0.5
urn spacing between frames. Image processing, including 3D reconstruction
and z-stack projections, was performed using FIJI.
In-vitro MRI scans
~ 100 uL of carbohydrate formulations were scanned in PBS buffer (2 mL glass
vials) after formation using a PharmaScan 7T micro MRI scanner. All in-vitro
MRI scans were conducted with a 3D mouse volume coil (Bruker RF volume
coil with 3 cm inner diameter).
T 1 RARE imaging
Ti weighted images were obtained by Ti weighted RARE imaging utilizing the
following settings: Flip angle: 90°. TR: 1000 ms. TE: 6.8 ms. Echo spacing: 6.8
ms, averages: 7, repetitions: 7 . Rare factor: 2 . Slice thicknes s : 0.7 mm, slice
package of 8 slices was generally applied. FOV: 20 X 20 mm2. Image size:256
X 256 voxels.
In-vivo MRI scans
-50-1 00 uL of carbohydrate formulations were injected subcutaneously on the
hip area of NMRI Nude mice. For intramuscular injection, -25 uL were injected
in the thigh area. Pain relief was not necessary, and the injected mice moved
around without problems. The mice were MRI scanned at specific timepoints
post injection (same day, 1 day, 1 week, 3 weeks (PLA-formulations only))
using a PharmaScan 7T micro MRI scanner. All in-vivo MRI scans were done
with a surface coil (Bruker RF surface coil, with a diameter of 2 cm).
T 1 RARE imaging
In-vivo Ti weighted images were obtained by Ti weighted RARE imaging
utilizing the following settings: Flip angle: 90°. TR: 1500 ms, TE: 8 ms, Echo
spacing: 8 ms, averages: 2, repetitions: 1, Rare factor: 4 . FOV: 35 X 35 mm2.
Image size: 256 X 256 voxels. Slice thickness: 0.7 mm, slice packages of ~9-
16 slices, depending on the volume of injected material, were applied.
T 1 RARE mapping
Ti values were obtained using saturation recovery experiments performed with
a T 1 map RARE sequence and 0.7 mm slices (package of 5-1 6 slices
depending on size and shape of injected material). Flip angle: 90°. TR's: 5500,
4000, 3000, 1500, 800, 400 and 200 ms. TE: 7.5 ms averages: 2, repetitions:
1. FOV: 35 χ 35 mm2, collected into a matrix of 192 192 voxels.
Image data processing and extraction of Ti from maps was performed on
ParaVision software version 6.0.1 . Ti maps were performed using a nonlinear
least square algorithm provided by the Image Sequence Analysis (ISA) tool of
ParaVision.
Results and discussion
Formulation of the injectable materials containing fluorophore labled lipids or
polymers were done by mixing the carbohydrate (lactose
octaacetate:octapropionate 1 : 1 or lactose octaisobutyrate), triglyceride
(glycerol trihexanoate (GTH) or glycerol trioctanoate (GTO)) containing
dissolved fluorophore functionalized material and eventual co-solvent
(propylene carbonate (PC) or ethanol (EtOH)) followed by ultrasonication until
homogeneity. Loading of Gd and Gd chelating polymers or lipids in similar
formulations was done by addition of acqueous solutions of these to the
polymer material followed by freeze-drying and the addition of triglyceride and
solvent as described above. While the carbohydrate confers structure to the
material, the triglyceride ensures the required softness for diffusion and the
added co-solvent helps enable diffusion of the added polymer/lipid to the
material interface.
In order to easily visualize which molecular structures were capable of diffusing
to the rim of the materials after injection and possibly provide Ti contrast,
formulations of fluorophore-functionalized lipids and polymers were examined
in-vitro by confocal microscopy after injection into PBS. The best performing
constructs were then functionalized with Gd-chelating moieties (DOPE/DTPA)
and MRI scanned in-vitro (in PBS) or in-vivo (s.c. or intramuscular injection in
mice) using a T 1 RARE sequence. The relaxativity of formulations with the
highest contrast was measured by T 1 RARE mapping.
Fluorophore labeled amphiphilic lipids (DOPE derivatives of Carboxy
Fluorescein (CF) or Rhodamine B (RhB)) were co-formulated with lactose
esters and different additives (See materials and methods). Formulations
based lactose octapropionate:octaaccetate 1: 1 (LAP) or lactose isobutyrate
(LI) and EtOH (25 wt%) displayed aggregated lipid particles throughout the
matrix, which would result in non-uniform contrast. The formulation based on
LAP and GTH (40%) displayed a uniform distribution of aggregated RhB-lipid
which would result in a lack of exposure of the majority of the Gd-chelates to
water and poor MRI contrast. However slight changes in the LAP: GTH
formulation by addition of a co-solvent (5% PC or 10% EtOH) resulted in a
clearly higher distribution of DOPE-RhB and DOPE-CF in the rim of the injected
formulation (Figure 2), as diffusion to the rim was facilitated by diffusion of
solvent. The same result was seen with the L I + 40% GTO-based formulation.
The mixture of the 40% GTO and L I provides a highly hydrophobic environment
in which the lipid tails are highly soluble, and the softness of the material makes
diffusion to the rim easy.
The formulations seen in Figure 2 were reconstructed with the two Gd-chelating
lipids, DOPE-DOTA (Gd) and BSA-DTPA(Gd), as it was hypothesized on the
basis of the confocal microscopy experiments, that formulations of similar Gd-
chelating constructs would diffuse to the rim of the materials resulting in MRI
Ti contrast. Maximum 3 mM of Gd-chelating lipid could be achieved in the
formulations due to solubility limitations. The in-vitro (PBS) and in-vivo (s.c.
injection of mice) results of the formulations are seen in Figure 3 and 4 . As
seen in Figure 3, BSA-DTPA(Gd) formulations produced a bright rim in both \n-
' and in-vivo, however DOPE-DOTA(Gd) produced a brighter rim, probably
due to DOTA being a more powerful chelator leading to a shorter Ti (-41 0 ms
in the material rim of DOPE-DOTA(Gd) vs ~ 1 188 ms of BSA-DTPA(Gd) in the
material rim in-vivo, day 1) (See table of Ti relaxation times in supporting
information). Both formulations, however, displayed clear leakage of Gd-
chelating lipid into the subcutaneous compartment at day 7 (seen by increased
bright area in the tissue around the injected material compared to day 1) , which
lead to decreased soft-tissue resolution. Smaller concentrations of Gd-
chelating lipids were therefore tested with DOPE-DOTA(Gd) formulations
(Figure 4). All visible concentrations of DOPE-DOTA(Gd) resulted in clear
leakage of lipid to the subcutaneous compartment, impairing soft tissue
resolution. Hence Gd-lipid based formulations were abandoned as MRI
markers. Instead, formulations containing Gd-chelating PLA constructs were
investigated to determine their contrast and stability in-vitro and in-vivo.
Figure 5 shows confocal microscopy images after injection into PBS of PLA-
RhB (Mn -3000 Da) co-formulated with the same components which worked
well for the DOPE-fluorophores: LAP 1:1 , 40% GTH + 5% PC and LI, 40%
GTO. The LI, 40% GTO formulation performs better in terms of uniform
situation of PLA-RhB in the rim of the material, while the LAP, 40% GTH, 5%
PC formulation provides less uniform situation of the RhB-polymer in the rim,
with more accumulation in the interior of the material. Both formulations display
the same tendencies a week after injection, showing a relatively high stability
of these formulations. Therefore, PLA-DOTA/DTPA (Gd) formulations were
subsequently investigated as MRI contrast agents. MRI in-vitro and in-vivo
results of PLA-DTPA(Gd) and PLA-DOTA(Gd) (~3 mM) formulated in the LAP
1: 1 , 40% GTH, 5% PC matrix are shown in Figure 6 . It was not possible to
formulate Gd-chelating polymers or lipids in the LI, 40% GTO matrix due to
precipitation in the formulations, therefore only the LAP based formulation was
investigated. The PLA-DOTA(Gd) formulation created a broad, more diffuse
rim, hard to distinguish from the subcutaneous fat, while the PLA-DTPA(Gd)
formulation resulted in a thin, sharp rim easily distinguishable from the
subcutaneous fat. The reason for the difference in quality of the MRI images of
the two formulations is not clearly known, however the different shape and
hydrophilicity of the chelating "head group" could influence diffusion properties
of the chelate as well as influence packing of the polymer on the surface of the
injected material.
Stability of the PLA-DTPA(Gd) formulation in terms of shape and contrast
enhancement, was investigated further both subcutaneously (s.c.) with
different concentrations of the chelate, and intramuscularly with the best
performing concentration, compared with a blank (Figure 7). The 3 mM PLA-
DTPA(Gd) formulation displays a clear white rim both subcutaneously and
intramuscularly, retaining contrast relatively well over the full study period of 3
weeks. The lower concentrations were relatively difficult to visualize and clearly
distinguish from the subcutaneous fat on MRI, although their rim seemed to
have a slightly higher Ti contrast enhancement than the rim of the blank
material (formulated 3 mM PLA without Gd). The high triglyceride content gives
the marker a very soft texture, which makes it prone to shape changes over
time, especially in moving muscle tissue, where fragmentation of the material
was observed probably also associated with the higher pressure and
complexity of muscle tissue compared to the s.c. compartment. The fragility of
the formulation can be modulated by lowering the triglyceride content, creating
a more stable material. Finally, to improve relaxativity, polymers (PLA/PLGA)
with multiple Gd-chelation sites can be synthesized and added to the
formulation instead of polymers with only one chelation site. This improvement
will likely increase Ti relaxation at the rim of the material creating a clearer,
more defined contrast between the interior material, the rim and the
surrounding tissue.
ln-vivo relaxativity of the PLA-DTPA(Gd) formulations imaged in Figure 7 along
with Ti contrast level over time of the 3 mM formulation (s.c.) is shown in Figure
8 . Due to only one concentration being efficient in enhancing Ti contrast,
relaxativity is very small, i.e. 0.1 59 +-0.024 mM S 1 . As a comparison, an
injectable contrast agent based on Gd-chelating polysaccharide nanogels
engineered by Chan et al [39], has a relaxativity of 5.4 mM s 1 at 7T, far
superior in relaxativity to due to the polyfunctional Gd-chelaton sites and high
water content of the material. The hydrophobic material with limited diffusion of
polymer to its surface as well as mono-functionalization of PLA with Gd-
chelator are the major reasons why the PLA-DTPA(Gd)-formulations from
Figure 7 display a low relaxativity. The 3 mM PLA-DTPA(Gd) formulation
however displays a fairly short Ti of -877 ms 1 week post injections, a value
which only changes slightly throughout the monitoring period. In comparison,
the blank material-rim displayed a Ti of 1400 ms, and the surrounding tissue
(s.c. or muscle) had an average Ti of -2600 ms. In order for the contrast
enhancement to be observable in a clinical setting, the product of relaxativity
and concentration (rl [C]) in the equation . = + r l [C] needs to give at
least 10% of the inherent relaxation rate ( 1 To) of the blank material and of the
surrounding tissue [21]. The 3 mM formulation gives a r l [C] of ~0.5s 1 , i.e.
-67% of the inherent Ti relaxation rate of the blank material and 124% of the
inherent relaxation rate of the surrounding tissue, so observable contrast is
clinically possible. The bright rims around the injected 3 mM formulations were
in average measured to be around ~ 1 mm in diameter, and resolutions up to
0.33 mm3 can be achieved on clinical 3T MRI scanners, even with short scan
times [22]. Hence, the 3 mM PLA-DTPA(Gd) does display promising results in
stability of contrast and contrast enhancement even for use in a clinical setup.
Specific embodiments of the present invention
Below some specific embodiments are listed.
According to one embodiment of the present invention, the clear contrast
distinction is bright vs dark in two different phases of the composition after
administration into the human or animal body. This is further seen in the
figures.
According to yet another embodiment of the present invention the
composition is intended for combined MR and CT imaging, and where the
composition is arranged to provide a clear distinction between CT contrast
and MRI contrast in a marker. As one example, CT may be only be seen in
the dark MR area.
Furthermore, according to one embodiment of the present invention, the
composition is a liquid before administration into the human or animal body
that increases in viscosity by more than 10,000 centipoise (cP) after
administration into the human or animal body. Moreover, the composition may
be arranged to be a liquid before administration and with the ability to
transform into a gel-like material after administration. Furthermore, the
composition may be provided to become a solid material after administration,
such as a crystalline or amorphous solid.
Moreover, according to yet another specific embodiment of the present
invention, said at least one imaging contrast agent is more concentrated on
the surface of the administered material after administration than inside the
administered material for at least 1 hour to 3 months after administration,
such as for at least 4 hours to 1 month, such as for at least 1 day to 2 months,
such as for at least 2 days to 3 months after administration. In another
embodiment, said at least one imaging contrast agent is more concentrated
less than 1 cm away from the administered material after administration than
inside the administered material for at least 1 hour to 3 months after
administration, such as for at least 4 hours to 1 month, such as for at least 1
day to 2 months, such as for at least 2 days to 3 months after administration.
Furthermore, according to one embodiment of the present invention, an
increase in viscosity after administration into the human or animal body is due
to diffusion of a solvent-like molecule out of the administered material and into
surrounding tissue.
According to one specific embodiment of the present invention, the non-water
soluble carbohydrates are disaccharides with structures selected from:
Formulae: I I I III
wherein Ri, R2, R3, R , R5, R6, R7, and Rs in formulae I , I I and III are selected
collectively from the group consisting of hydrogen, alkanoyi, hydroxyl-
substituted alkanoyi, and acyloxy-substituted alkanoyi, alkanyl,
hydroxysubstituted alkanyl and acyloxy substituted alkanyl; or wherein Ri, R2,
R3, R , R5, Re, R7, and Rs are independently selected from the group
consisting of hydrogen, alkanoyi, hydroxyl-substituted alkanoyi, and acyloxy-
substituted alkanoyi, alkanyl, hydroxysubstituted alkanyl and acyloxy
substituted alkanyl;
or wherein all groups of Ri, R2, R3, R , R5, Re, R7, and Rs are selected
collectively from the group consisting of acetyl, isobutyryl or propionyl; or
wherein Ri, R2, R3, R , R5, Re, R7, and Rs are independently selected from the
group consisting acetyl, isobutyryl or propionyl;
and wherein both pure anomers and mixtures of a- and β- anomers of the
above mentioned structural variations are claimed.
According to yet another embodiment, the non-water soluble carbohydrates
are trisaccharides with structures selected from:
Formulae IV:
wherein Ri, R2, R3, R , R5, R6, R7, Rs, R9, R10 and R 11 in formulae IV are
selected collectively from the group consisting of hydrogen, alkanoyi,
hydroxyl-substituted alkanoyi, and acyloxy-substituted alkanoyi, alkanyl,
hydroxysubstituted alkanyl and acyloxy substituted alkanyl; or wherein Ri, R2,
F , F , Rs, Re, R7, Rs, Rg, R10 and R 11are independently selected from the
group consisting of hydrogen, alkanoyi, hydroxyl-substituted alkanoyi, and
acyloxy-substituted alkanoyi, alkanyl, hydroxysubstituted alkanyl and acyloxy
substituted alkanyl;
or wherein all groups of R i , R2, R3, R , Rs, Re, R7, Rs, Rg, R10 and R 11are
selected collectively from the group consisting of acetyl, isobutyryl or
propionyl; or wherein R i , R2, R3, R , Rs, Re, R7, Rs, Rg, R10 and R 11are
independently selected from the group consisting acetyl, isobutyryl or
propionyl;
and wherein both pure anomers and mixtures of a- and β- anomers of the
above mentioned structural variations are claimed.
At least 50% of the non-water soluble carbohydrates may be mono- or
oligosaccharides containing at least one amino sugar unit. Moreover,
according to another embodiment, the amino sugar has the structure:
wherein R i , R2, R3, R and Rs in formulae V are selected collectively from the
group consisting of hydrogen, alkanoyi, hydroxyl-substituted alkanoyi, and
acyloxy-substituted alkanoyi, alkanyl, hydroxysubstituted alkanyl and acyloxy
substituted alkanyl; or wherein R i , R2, R3, R and Rs are independently
selected from the group consisting of hydrogen, alkanoyi, hydroxyl-substituted
alkanoyi, and acyloxy-substituted alkanoyi, alkanyl, hydroxysubstituted
alkanyl and acyloxy substituted alkanyl, and mono-, di-, tri- or tetra-
saccharide derivatives;
or wherein all groups of R i , R2, R3, R and Rs are selected collectively from
the group consisting of acetyl, isobutyryl or propionyl; or wherein Ri, R2, R3,
R and Rs are independently selected from the group consisting acetyl,
isobutyryl or propionyl;
and wherein both pure anomers and mixtures of anomers such as a- and β-
anomer centres of the above mentioned structural variations are claimed.
According to one specific embodiment, the non-water soluble carbohydrates
comprises poly(ethylene glycol-b-caprolactone) (PEG-PCI), sucrose acetate
isobutyrate (SAIB), poly(D,/_-lactic acid), or poly(lactic-co-glycolic acid)
(PGLA), or a combination thereof. According to another embodiment, the non-
water soluble carbohydrates comprise mixed saccharides of furanose and
pyranose.
Moreover, according to one specific embodiment of the present invention,
said at least one imaging contrast agent makes the composition visible by
PET imaging, SPECT imaging, Ultrasound imaging, CT imaging, MR imaging,
x-ray imaging, fluoroscopy imaging, fluorescence imaging, or OCT imaging.
Moreover, according to yet another embodiment, the composition contains
two imaging contrast agents that are visible by at least two imaging methods,
such as visible by at least two imaging methods chosen from PET imaging,
SPECT imaging, Ultrasound imaging, CT imaging, MR imaging, x-ray
imaging, fluoroscopy imaging, fluorescence imaging, or OCT imaging.
Furthermore, according to one embodiment of the present invention the
composition contains an imaging contrast agent for CT imaging and an
imaging contrast agent for MR imaging.
According to one specific embodiment of the present invention, the
composition contains an MR imaging contrast agent containing Gadolinium
associated with a chelate. The composition may contain an MR imaging
contrast agent containing Gadolinium associated with a chelate that is
covalent linked to a polymer. Moreover, the composition may contain an MR
imaging contrast agent containing Gadolinium associated with a chelate that
is covalent linked to poly lactic acid (PLA). Moreover, the composition may
contain an MR imaging contrast agent containing Gadolinium associated with
a chelate chosen from PLA-DTPA or PLA-DOTA polymer chelates.
Furthermore, the composition may contain a CT contrast agent and an MR
imaging contrast agent containing Gadolinium associated with a chelate, and
wherein the CT contrast agent is hydrophobic. As mentioned before, the
hydrophobic CT contrast agent may be relatively uniformly distributed
throughout the whole formulation, and the amphiphilic Gd-chelating
constructs are capable of diffusing to the rim.
According to one embodiment, the composition comprises a
pharmacologically active compound that is released into the surrounding
tissue, such as chemotherapy that enhances the effect of radiotherapy.
Furthermore, according to yet another specific embodiment the composition is
intended to be administered to the human or animal body through a syringe,
an endoscope or a bronchoscope to the target tissue preferably wherein the
composition after insertion into the human or animal body constitutes a
medical or surgical implant for tissue or surgical adhesion which preferably is
wound dressing, a hemostat, enhances tissue regeneration, is a void filler.
The present invention also embodies a medical or surgical implant comprising
a composition according to the present invention, wherein the composition is
part of a sprayable composition.
Moreover, the present invention provides a composition system which may be
used as a tissue marker for guided surgery and/or imaging by one or multiple
imaging modalities. The composition system may allow for detection of the
tissue marker by an external imaging modality if administered or implanted
into a mammalian body. Exemplary external imaging modalities include, but
are not limited to, X-ray imaging, such as CT imaging, MRI, PET imaging,
single photon emission computed tomography (SPECT) imaging, nuclear
scintigraphy imaging, ultrasonography imaging, ultrasonic imaging, near-
infrared imaging and/or fluorescence imaging.
Examples
Example 1: Synthesis of carbohydrate esters
General experimental conditions: All reactions were carried out under inert
atmosphere (N2). Water sensitive liquids and solutions were transferred via
syringe. Water used for washing of the isolated products was in all cases MilliQ
water. Organic solutions were concentrated by rotary evaporation at 30-60°C
at 200-0 mbar. Thin layer chromatography (TLC) was carried out using
aluminum sheets pre-coated with silica 60F (Merck 5554). The TLC plates were
inspected under UV light or developed using a cerium ammonium sulphate
solution ( 1% cerium (IV) sulphate and 2.5% hexa-ammonium molybdate in a
10% sulfuric acid solution).
Reagents: DOTA-NHSwas purchased from Macrocyclics. All other chemicals were
purchased from Sigma Aldrich and were used as received. Dry pyridine was
obtained by drying over molecular sieves (4A) for 2-3 days prior to use.
Instrumentation: Nuclear Magnetic Resonance (NMR) was conducted on a
Bruker Ascend™ 400 MHz - operating at 401 .3 MHz for H and 100.62 MHz for
3C - with a 5 mm H - Broadband Dual Channel z-gradient Prodigy cryoprobe
at 298 K using the residual solvent as internal standard. All coupling constants
(J) are expressed in Hz. The FID files were processed in Mnova Suite. In H-
NMR spectra of ,β anomeric mixtures, the integral of H-1 of the most abundant
anomer was always set to 1.0, and the percentage of each anomeric species
was calculated from the integral ratio of H-1 a and H-1 β. MALDI-TOF MS was
conducted on a Bruker Autoflex Speed™ mass spectrometer. The matrix used
for MALDI-TOF was a mixture of 2,5 dihydroxy benzoic acid (DHB) spiked with
sodium trifluoroacetate in ethanol (60mg/mL).
General experimental procedure for synthesis of carbohydrate esters
Lactose (typically 10-1 00 g) was suspended in dry pyridine under inert
atmosphere (N2). Hereafter, acetic, propionic or isobutyric anhydride (2.2 eq.
pr. hydroxyl group) was carefully added. Then, a catalytic amount of DMAP (0.1
eq.) was added. The reactions were heated to 48°C overnight, and then
continued for -24 hours at room temperature, until TLC and MALDI-TOF
showed complete acylation of the starting material. The reactions were
concentrated under reduced pressure and co-evaporated with toluene. The
concentrates were dissolved in CHCb and washed with NaHCO3 (aq.) (5x),
brine ( 1 x ) and water ( 1 x). The organic phases were dried with MgSO (s),
filtered, concentrated under reduced pressure and dried in vacuo. Yields and
reported spectra of individual sugar esters can be found below.
α,β lactose octaacetate
Yield: 93.7 % yield (mixture of anomers: -30% a and -70 % ) .1H-NMR: (400
MHz, Chloroform-d) δ 6.24 (d, J = 3.7 Hz, 1H, H-1 a), 5.66 (d, J = 8.3 Hz, 1H,
H-1 β) , 5.44 (dd, 10.28, 9.53 Hz, 0.4 H), 5.37 - 5.31 (m, 2H), 5.23 (t, J = 9.1
Hz, 1H), 5.1 5 - 5,00 (m, 3H), 4.99 - 4.91 (m, 2H), 4.50 - 4.41 (m, 3H), 4.1 7 -
4.05 (m, 4H), 3.99 (ddd, J = 10.2, 4.3, 2.1 Hz, 0.4H, H5 a), 3.91 - 3.78 (m, 3H),
3.75 (ddd, J = 9.9, 4.8, 2.0 Hz, 1H, H5 β) , 2.1 9-1 .93 (singlets, -32 H, CH3
acetyls). MALDI TOF-MS: Calc [M+ Na] +: 701 .59. Found: 701 .51 .
,β lactose octapropionate
Yield: 84% (mixture of anomers: -30% a and -70 % β) . 1H-NMR (400 MHz,
Chloroform-d) δ 6.26 (d, J = 3.7 Hz, 1H, H 1-a), 5.68 (d, J = 8.3 Hz, 1H, H-1 β) ,
5.47 (dd,1 0.3, 9.2 Hz,0.4 H), 5.38 - 5.33 (m, 2H), 5.26 (t, J = 9.2 Hz, 1H), 5.1 5
-5.00 (m, 3H), 5.02 - 4.91 (m, 2H), 4.49 - 4.41 (m, 3H), 4.1 5 - 4.03 (m, 4H),
3.98 (ddd, J = 10.1 , 3.9, 1.8 Hz, 0.4 H, H5 a), 3.91 - 3.77 (m, 3H), 3.73 (ddd, J
= 9.9, 4.6, 2.0 Hz, 1H, H5 β) , 2.47 - 2.1 5 (m, -23H), 1. 1 9 - 0.99 (m, -34H).
MALDI TOF-MS: Calc [M+ Na]+: 8 13.80. Found: 8 13.42.
α,β lactose octaisobutyrate
Yield: 89.5% (mixture of anomers: -30% a and -70 % β) . 1H NMR (400 MHz,
Chloroform-d) δ 6.26 (d, J = 3.8 Hz, 1H, H-1a), 5.68 (d, J = 8.3 Hz, 1H, Η- 1 β) ,
5.48 (dd, J = 10.3, 9.3 Hz, 0.4 H), 5.40 - 5.34 (m, 2H), 5.27 (t, J = 9.5 Hz, 1H),
5.1 8 - 5.00 (m, 3H), 5.03 - 4.91 (m, 2H), 4.50 - 4.41 (m, 3H), 4.24 - 4.02 (m,
~4H), 3.95 (ddd, J = 10 . , 3.8, 1.7 Hz, 0.4H, H5 a), 3.91 - 3.80 (m, 3H), 3.70
(ddd, J = 9.9, 4.5, 2.0 Hz, 1H, H5 β) , 2.70 - 2.32 (m, ~ 1 1H), 1.26 - 1.01 (m,
-68 H). MALDI TOF-MS: Calc [M+ Na]+: 926.02. Found: 925.70.
Example 2 : Synthesis of fluorecently labled PLA
PLA-RhB
PLA-NH2 (Mn -2500) (260 mg, 0.1 mmol) was suspended in dry DCM (-5 mL).
Then, a pre-mixed mixture of Rhodamine-B ( 105, 0.2 mmol), EDC-HCI (80 mg,
0.4 mmol) and DMAP ( 106 mg, 0.9 mmol) dissolved in 5 mL dry DCM was
added, and the reaction was continued at r.t. for 2 days, where Kaiser test was
negative, indicating full functionalization. The solvents were removed in vacuo,
and the crude mixture was dissolved in DMSO and purified by dialysis (Mw
cutoff: 1000 da) against MQ water for 14 days. Yield: 299 mg (97%). 1H NMR
(400 MHz, DMSO- ) δ 8.31 (d (br), J = 7.7 Hz, 1H), 7.95 (br. t , J = 7.4 Hz,
1H), 7.87 (br. t , J = 7.6 Hz, 1H), 7.57 - 7.44 (m, 2H), 7.05 - 7.00 (m, 1H), 6.39
- 6.24 (m, ~5H), 5.20 (q, J = 7.1 Hz, ~33H), 3.65 (dd (br), J=1 3.8, 6.9 Hz, 4H),
3.31 (br. q, J = 7.1 Hz, 8H), 3.1 2 - 2.94 (m, 2H), 1.47 (d, J = 7.1 Hz, ~99H),
1.08 (t, J = 6.9 Hz, 12H).
Example 3 : Synthesis of Gd-chelators
DOPE-DOTA
Diacylphosphatidylethanolamine (DOPE) ( 12 mg, 0.01 6 mmol) was suspended
in dry dichloromethane (3 ml_), followed by addition of DOTA-NHS (-1 8 mg,
0.036 mmol) and triethyl amine (50 µ Ι_). The reaction was continued for 2.5
days at r.t., where after kaisertest (negative) and MALDI-TOF of the reaction
mixture indicated completion. The solvent was removed in vacuo, and the
crude mixture was dissolved in MeOH:H20 40:60 and purified by preparative
HPLC (Xterra C8 column, MeCN/H 20/TFA system. Gradient: 50->1 00% MeCN
in 10 minutes). Yield: 13.5 mg, 74%. 1H NMR (400 MHz, Chloroform-d) δ 7.93
(s, 1H), 5.39 - 5.28 (m, 5H), 5.21 (dddd (br), J = 5.6, 3.0 Hz, 1H), 4.32 (dd, J =
12.0, 3.1 Hz, 1H), 4.09 (dd, J = 12.1 , 6.8 Hz, 1H), 3.95 - 3.78 (m, 4H), 3.49
(dd, J = 14.6, 7.3 Hz, 8H) 3.09 (dd, J = 14.6, 7.3 Hz, ~ 15 H), 2.63 (s, 4H), 2.25
(dt, J = 10.0, 7.5 Hz, 4H),1 .97 (q, J = 6.4 Hz, 8H), 1.40 - 1. 1 3 (m, ~40H), 0.84
(t, 6H). MALDI-TOF MS: Calc [M+ H]+: Calc 113 1 .45, Found: 113 1 .5.
PLA-DTPA
PLA-NH2 (Mn -2500) (260 mg, 0.1 mmol) was suspended in dry pyridine ( 1 0
ml_) followed by addition of DTPA-dianhydride (57.5 mg, 0.1 6 mmol) and a
catalytic amount of DMAP ( 1 .3 mg, 0.01 mmol). The reaction was continued for
1.5 day, where Kaiser test (negative) indicated the reaction was completed. 5
ml_ MQ water was added and stirred for 2 h to hydrolyze any residual
anhydride. The solvents were removed in vacuo, and the crude mixture was
dissolved in DMSO and purified by dialysis (Mw cutoff: 1000 da) against MQ
water for 10 days. Yield: 285 mg (96%). H NMR (400 MHz, DMSO- ) δ 8.09
(t, J=5.08 Hz, NH, 1 H), 5.20 (q, J = 7.0 Hz, ~33H), 5.47 (s, 1 H, OH), 4.21 (q,
J = 7.0 Hz, 2H), 4.1 7 - 4.01 ( m, 2H)), 3.69 - 3.21 (m, 10H), 3.1 4 (q, J= 7.0
Hz, ~2H ) , 3.06 - 2.81 (m, ~6H), 1.74 (p, J = 7.0 Hz, 2H), 1.47 (d, J = 7.0 Hz,
~99H).
PLA-DOTA
PLA-NH2 (Mn -2500) (80 mg, 0.032mmol) was suspended in dry
dichloromethane (3 mL), followed by addition of DOTA-NHS (35 mg, 0.0704
mmol) and triethyl amine (40 µ Ι_). The reaction was continued for 2.5 days at
r.t., where Kaiser test (negative) indicated completion. The solvent was
removed in vacuo, and the crude mixture was dissolved in DMSO and purified
by dialysis (Mw cutoff: 1000 da) against MQ water for 8-1 0 days. Yield: 89.6
mg (97%). 1H NMR (400 MHz, DMSO- ) δ 8.23 (s, NH, ~ 1 H), 5.21 (q, J = 7.0
Hz,~ 33H), 4.21 (q, J =7.0 Hz, 2H), 4.1 6 - 3.99 (m, 2H), 3.49 - 3.34 (m, 6H),
3.24 - 3.03 (m, 4H), 3.03 - 2.87 (m, ~9H), 2.70 - 2.61 (m, 4H), 1.79 (p, J = 7.0
Hz, 2H), 1.63 (d, J = 7.1 Hz, 1H), 1.47 (d, J = 7.0 Hz, ~99H).
Example 4 : ln-vitro confocal microscopy of markers
containing fluorescent amphiphiles
Laser scanning confocal microscopy was conducted using a Leica TCS SP5
Scanning Laser Confocal Microscope (61 x wet objective, 561 nm excitation
DPPS Laser) on 5-1 0 uL volumes of different marker compositions (see Table
1) in PBS buffer in order to investigate distribution of fluorescently labled
amphiphiles in the markers. A predominant distribution to the marker rim
indicates the possibility of primary contrast enhancement at the marker rim
when formulating the corresponding Gd chelators. The markers were prepared
in 8 well microscope slides containing PBS buffer and imaged the same day.
Multiple images were acquired for each sample with a 0.5 um spacing between
z-stack frames. Image processing was performed using FIJI. All formulations
listed in Table 1 show predominant accumulation of fluorophore at the marker-
water interface. Representative results are shown in Figure 9 .
Table 1. Specifications for preparation of fluorophore containing marker
formulations. LAP 1: 1 : Lactose octaacetate:octapropionate 1: 1 . LOIB: Lactose
octaisobutyrate. GTH: Glycerol trihexanoate. GTO: Glycerol trioctanoate. PC:
Propylene carbonate. EtOH: Ethanol. PLA: Poly-(L-lactide). DOPE:
Diacylphosphatidylethanolamine, RhB: Rhodamine B. CF: Carboxy
fluorescein.
Example 5 : ln-vitro MRI imaging of markers
Single markers (-50 µ Ι_) containing 3 mM concentrations of different Gd-
chelators (see Table 2) were injected into 2 mL glass vials containing PBS
buffer and investigated using a PharmaScan 7T micro MRI scanner by T 1
RARE imaging (Flip angle: 90°. TR: 1000 ms. TE: 6.8 ms. Echo spacing: 6.8
ms, averages: 7, repetitions: 7 . Rare factor: 2 . Slice thicknes s : 0.7 mm, slice
package of 8 . FOV: 20 X 20 mm2. Resolution: 256 X 256 voxels) in order to
visualize T 1 enhancement at the marker-water interface. The markers were
MRI scanned while still in the PBS vials within 1 week after injection. All scans
were conducted using a 3D mouse volume coil (Bruker RF volume coil with 3
cm inner diameter). Image data processing was performed on ParaVision
software version 6.0.1 . All markers displayed Ti contrast enhancement at the
marker-water interface. The results are shown in Figure 10.
Table 2. Specifications for preparation of Gd-containing marker formulations
for in-vitro MRI scan. LAP 1 : 1 : Lactose octaacetate:octapropionate 1 : 1 . GTH:
Glycerol trihexanoate. PC: Propylene carbonate. PLA: Poly-(L-lactide). DOPE:
Diacylphosphatidylethanolamine, BSA: Bis(stearylamide). DOTA: 1,4,7,1 0-
tetra-azacyclododecane-1 ,4,7,1 0-tetraacetic acid. DTPA:
diethylenetriaminepentaacetic acid. x-SAIB: 6,6'-di-triidobenzene-isobuturic-
sucrose.
l -vivo Ti values
Table 3: ln-vivo Ti relaxation table of material rims formulated with the above
listed species in the stated concentrations. Base formulation was in all cases
the LAP 1:1, 40% GTH, 5% PC matrix.
Example 6 : ln-vivo CT and MRI imaging of subcutaneous
markers
6.1 : The formulations from Example 5 were injected in 50 µ Ι_ volumes
subcutaneously in the hind leg of NMRI Nude mice (n=1 for each formulation).
The mice were MRI and CT scanned 1 day and 1 week post injection, utilizing
the same scanners, software and coil as in Example 5 . Both CT scan (Inveon
small animal CT scanner (Siemens Medical Systems), processsing performed
on Inveon software), T 1 RARE imaging (Flip angle: 90°. TR: 1500 ms, TE: 8
ms, Echo spacing: 8 ms, averages: 2, repetitions: 1, Rare factor: 4 . FOV: 35 X
35 mm2. Resolution: 256 X 256 voxels. Slice thickness: 0.7 mm, slice packages
of -9-1 6 depending on marker size) and T 1 RARE mapping (Flip angle: 90°.
TR's: 5500, 4000, 3000, 1500, 800, 400 and 200 ms. TE: 7.5 ms, Echo
spacing: 7.5 ms. Rare factor: 2 . Averages: 2, repetitions: 1. FOV: 35 χ 35 mm2,
collected into a matrix of 192 192 voxels, slice packages of -9-1 6 depending
on marker size) was performed, in order visualize the markers as well as
measure the Ti relaxation time at the marker rim. Data processing was
performed on ParaVision software version 6.0.1 . While the Gd-chelating lipids
seemed to leak out of the marker over time, the Gd-chelating PLA analogues
did not result in visible leakage but seemed to stay predominantly at the
marker-water interface, causing a bright Ti enhancement of the marker rims.
The results from day 7 are shown in Figure 11 .
6.2: The best performing formulation from Figure 11, with the clearest contrast
enhancement (Figure 11 a-b. Formulation 3, Table 2), was, injected
subcutaneously along with an additional formulation containing 20%
triglyceride (see Table 4) in the hind leg of NMRI Nude mice ( -50 µ Ι_volumes,
n=4). The mice were then CT and MRI scanned at specific timepoints post
injection ( MRI: 1 day, 1 week , 2 weeks, 3 weeks, 4 weeks and 6 weeks. CT:
week 1, 3 and 6) in order to assess marker volumes, as well as CT and MRI
(Ti) contrast enhancement over time. The same scan methods, software and
equipment as described in 6.1 was employed. All markers displayed Ti
enhancement and high CT contrast enhancement over the entire study period.
After ended study, the mice were euthanized and the markers removed
surgically, no visible irritation or inflammation was present around the markers.
The results are shown in Figure 12.1 and 12.2.
Table 4. Specifications for preparation of Gd-containing marker formulations
for 6-week study in-vivo of subcutaneous markers. LAP 1 : 1 : Lactose
octaacetate:octapropionate 1 : 1 . GTH: Glycerol trihexanoate. PC: Propylene
carbonate. PLA: Poly-(L-lactide). DTPA: diethylenetriaminepentaacetic acid x-
SAIB: 6,6'-di-triidobenzene-isobuturic-sucrose.
Example 7 : ln-vivo CT and MRI imaging of intramuscular
marker
Formulation 1 from Table 4 , Example 6.2 (25 µ Ι_) was injected into the thigh
muscle of an NMRI Nude mouse to monitor marker stability in frequently
moving tissue. The mouse did not show any signs of pain or difficulty moving
around, the weight of the mouse also remained stable throughout the
experiment. MRI scan was conducted 7 days post injection using the same
scanner, T 1 RARE scan method and coil as listed in Example 6.1 . Image
processing was performed on ParaVision software version 6.0.1 . At 7 days post
injection, CT scan of the marker was also performed on the same equipment
as listed in Example 5-6. The MRI images showed Ti enhancement at the
marker rim. The results are shown in Figure 13.
Conclusion
The lactose acetatepropionate 1: 1 formulation containing 3 mM PLA-
DTPA(Gd), 40% GTH and 5% PC performed well as dual MRI and CT marker
over the observation period of 3 weeks. The stable Ti contrast enhancement
displayed sufficient strength and sufficient resolution making it amenable to be
observable in patients when using standard clinical MRI facilities and setup.
These agents have the potential to result in a novel, commercially applicable,
injectable marker for treatment planning and monitoring during IGRT. Future
development includes adjusting the triglyceride level and addition of
polyfunctional Gd-chelating polymers to achieve both enhanced Ti contrast as
well as a stable 3D structure optimal for tracking in-vivo.
Abbreviations
BSA: Bis(Stearylamide)
CF: Carboxyfluorescein
CT: Computed Tomography
DOPE: Diacylphosphatidylethanolamine
DOTA: ,4,7,1 0-tetra-azacyclododecane-1 ,4,7,1 0-tetraacetic acid.
DTPA: diethylenetriaminepentaacetic acid
EBUS: Endobronchial Ultrasound
EDC: 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide.
EtOH: Ethanol
EUS: Endoscopic Ultrasound
G : Gauge ("needle size")
GTH: Glycerol Trihexanoate
GTO: Glycerol Trioctanoate
IGRT: Image Guided Radiotherapy
LAP: Lactose octaacetate:octapropionate 1 :1
LI: Lactose octaisobutyrate
MALDI-TOF: Matrix assisted laser desorption/ionization time-of-flight mass
spectrometry.
MRI: Magnetic Resonance Imaging
PBS: Phosphate Buffered Saline
PC: Propylene Carbonate
PLA: Polylactic Acid
RARE: Rapid Acquisition with Relaxation Enhancement
RhB: Rhodamine B
RT: Radio Therapy
SAIB: Sucrose Acetate Isobutyrate
S.C.: Subcutaneous
T : Tesla
Ti : Longitudinal relaxation
T2: Transverse relaxation
TE: Echo time
TLC: Thin Layer Chromatography
TR: Repetition Time
Wt%: Weight %
XSAIB: 6,6'-di-triidobenzene-isobuturic-sucrose or lodoSAIB
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Claims
1. A composition for at least MR imaging, comprising non-water soluble
carbohydrates, wherein at least 50% of the non-water soluble carbohydrates
are carbohydrates selected from derivatives of lactose, maltose, trehalose,
raffinose, glucosamine, galactosamine, lactosamine, sucrose or derivatives of
sucrose, or mixed saccharides, or derivatives of disaccharides with at least
two pyranose saccharide units, trisaccharides, tetrasaccharides, or mixtures
thereof, and wherein the composition is a liquid before administration into the
human or animal body and increases in viscosity by more than 1,000
centipoise (cP) after administration, for use as a medicament, wherein the
composition contains at least one imaging contrast agent, and wherein the
composition provides a phase separation which provides a clear contrast
distinction in MR imaging.
2 . The composition according to claim 1, wherein the clear contrast distinction
is bright vs dark in two different phases of the composition after administration
into the human or animal body.
3 . The composition according to claim 1 or 2, wherein the composition is
intended for combined MR and CT imaging, and wherein the composition is
arranged to provide a clear distinction between CT contrast and MRI contrast
in a marker.
4 . The composition according to any of the preceding claims, wherein the
composition is a liquid before administration into the human or animal body
that increases in viscosity by more than 10,000 centipoise (cP) after
administration into the human or animal body.
5 . The composition according to any of the preceding claims, wherein the
composition is a liquid before administration and has the ability to transform
into a gel-like material after administration.
6 . The composition according to any of the preceding claims, wherein the
composition becomes a solid material after administration, such as a
crystalline or amorphous solid.
7 . The composition according to any of the preceding claims, wherein said at
least one imaging contrast agent is more concentrated on the surface of the
administered material after administration than inside the administered
material for at least 1 hour to 3 months after administration, such as for at
least 4 hours to 1 month, such as for at least 1 day to 2 months, such as for at
least 2 days to 3 months after administration.
8 . The composition according to any of the preceding claims, wherein said at
least one imaging contrast agent is more concentrated less than 1 cm away
from the administered material after administration than inside the
administered material for at least 1 hour to 3 months after administration,
such as for at least 4 hours to 1 month, such as for at least 1 day to 2 months,
such as for at least 2 days to 3 months after administration.
9 . The composition according to any of the preceding claims, wherein an
increase in viscosity after administration into the human or animal body is due
to diffusion of a solvent-like molecule out of the administered material and into
surrounding tissue.
10 . The composition according to any of claims 1-9, wherein the non-water
solubl
Formulae: I I I
wherein R i , R2, R3, R , R5, R6, R7, and Rs in formulae I , I I and III are selected
collectively from the group consisting of hydrogen, alkanoyi, hydroxyl-
substituted alkanoyi, and acyloxy-substituted alkanoyi, alkanyl,
hydroxysubstituted alkanyl and acyloxy substituted alkanyl; or wherein R i , R2,
R3, R , R5, Re, R7, and Rs are independently selected from the group
consisting of hydrogen, alkanoyi, hydroxyl-substituted alkanoyi, and acyloxy-
substituted alkanoyi, alkanyl, hydroxysubstituted alkanyl and acyloxy
substituted alkanyl;
or wherein all groups of R i , R2, R3, R , R5, Re, R7, and Rs are selected
collectively from the group consisting of acetyl, isobutyryl or propionyl; or
wherein R i , R2, R3, R , R5, Re, R7, and Rs are independently selected from the
group consisting acetyl, isobutyryl or propionyl;
and wherein both pure anomers and mixtures of a- and β- anomers of the
above mentioned structural variations are claimed.
11. The composition according to any of claims 1-9, wherein the non-water
soluble carbohydrates are trisaccharides with structures selected from:
Formulae
wherein R i , R2, R3, R4, R5, R6, R7, Rs, R9, R10 and R 11 in formulae IV are
selected collectively from the group consisting of hydrogen, alkanoyi,
hydroxyl-substituted alkanoyi, and acyloxy-substituted alkanoyi, alkanyl,
hydroxysubstituted alkanyl and acyloxy substituted alkanyl; or wherein R i , R2,
R3, R , Rs, Re, R7, Rs, Rg, R10 and R 11are independently selected from the
group consisting of hydrogen, alkanoyi, hydroxyl-substituted alkanoyi, and
acyloxy-substituted alkanoyi, alkanyl, hydroxysubstituted alkanyl and acyloxy
substituted alkanyl;
or wherein all groups of R i , R2, R3, R , Rs, Re, R7, Rs, Rg, R10 and R 11are
selected collectively from the group consisting of acetyl, isobutyryl or
propionyl; or wherein R i , R2, R3, R , Rs, Re, R7, Rs, Rg, R10 and R 11are
independently selected from the group consisting acetyl, isobutyryl or
propionyl;
and wherein both pure anomers and mixtures of a- and β- anomers of the
above mentioned structural variations are claimed.
12 . The composition according to any of claims 1-9, wherein at least 50% of
the non-water soluble carbohydrates are mono- or oligosaccharides
containing at least one amino sugar unit.
13 . The composition according to claim 12, wherein the amino sugar has the
structure:
Formulae V:
wherein Ri, R2, R3, R and Rs in formulae V are selected collectively from the
group consisting of hydrogen, alkanoyi, hydroxyl-substituted alkanoyi, and
acyloxy-substituted alkanoyi, alkanyl, hydroxysubstituted alkanyl and acyloxy
substituted alkanyl; or wherein Ri, R2, R3, R and Rs are independently
selected from the group consisting of hydrogen, alkanoyi, hydroxyl-substituted
alkanoyi, and acyloxy-substituted alkanoyi, alkanyl, hydroxysubstituted
alkanyl and acyloxy substituted alkanyl, and mono-, di-, tri- or tetra-
saccharide derivatives;
or wherein all groups of Ri, R2, R3, R and Rs are selected collectively from
the group consisting of acetyl, isobutyryl or propionyl; or wherein Ri, R2, R3,
R and Rs are independently selected from the group consisting acetyl,
isobutyryl or propionyl;
and wherein both pure anomers and mixtures of anomers such as a- and β-
anomer centres of the above mentioned structural variations are claimed.
14 . The composition according to any of claims 1-9, wherein the non-water
soluble carbohydrates comprises poly(ethylene glycol-b-caprolactone) (PEG-
PCI), sucrose acetate isobutyrate (SAIB), poly(D,/_-lactic acid), or poly(lactic-
co-glycolic acid) (PGLA), or a combination thereof.
15 . The composition according to any of claims 1-9, wherein the non-water
soluble carbohydrates comprise mixed saccharides of furanose and
pyranose.
16 . The composition according to any of the preceding claims, wherein said at
least one imaging contrast agent makes the composition visible by PET
imaging, SPECT imaging, Ultrasound imaging, CT imaging, MR imaging, x-
ray imaging, fluoroscopy imaging, fluorescence imaging, or OCT imaging.
17 . The composition according to any of the preceding claims, wherein the
composition contains two imaging contrast agents that are visible by at least
two imaging methods, such as visible by at least two imaging methods
chosen from PET imaging, SPECT imaging, Ultrasound imaging, CT imaging,
MR imaging, x-ray imaging, fluoroscopy imaging, fluorescence imaging, or
OCT imaging.
18 . The composition according to any of the preceding claims, wherein the
composition contains an imaging contrast agent for CT imaging and an
imaging contrast agent for MR imaging.
19 . The composition according to any of the preceding claims, wherein the
composition contains an MR imaging contrast agent containing Gadolinium
associated with a chelate.
20. The composition according to any of the preceding claims, wherein the
composition contains an MR imaging contrast agent containing Gadolinium
associated with a chelate that is covalent linked to a polymer.
2 1 . The composition according to any of the preceding claims, wherein the
composition contains an MR imaging contrast agent containing Gadolinium
associated with a chelate that is covalent linked to poly lactic acid (PLA).
22. The composition according to any of the preceding claims, wherein the
composition contains an MR imaging contrast agent containing Gadolinium
associated with a chelate chosen from PLA-DTPA or PLA-DOTA polymer
chelates.
23. The composition according to any of the preceding claims, wherein the
composition contains a CT contrast agent and an MR imaging contrast agent
containing Gadolinium associated with a chelate, and wherein the CT contrast
agent is hydrophobic.
24. The composition according to any of the preceding claims, wherein the
composition comprises a pharmacologically active compound that is released
into the surrounding tissue, such as chemotherapy that enhances the effect of
radiotherapy.
25. The composition according to any of the preceding claims, arranged to
be administered to the human or animal body through a syringe, an
endoscope or a bronchoscope to the target tissue preferably wherein the
composition after insertion into the human or animal body constitutes a
medical or surgical implant for tissue or surgical adhesion which preferably is
wound dressing, a hemostat, enhances tissue regeneration, is a void filler.
26. A medical or surgical implant comprising a composition according to any
of the preceding claims, wherein the composition is part of a sprayable
composition.
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